ArticleBMC complementary medicine and therapies2026
Gentiopicroside inhibits HMGCR/NF-κB pathway to alleviate renal fibrosis.
Article in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundGentiopicroside (GSP) has been shown to effectively ameliorate renal fibrosis (RF), yet its underlying mechanisms are poorly characterized. This study investigates how GSP alleviates RF using RNA-seq and in vitro experiments.
methodFirst, an RF cell model was established through TGF-β induced HK-2 cells. The therapeutic effect of GSP on RF was evaluated in vitro through CCK-8 and Transwell assays. RNA-seq was used to identify potential targets of GSP in treating RF, followed by PPI analysis, GO and KEGG enrichment analyses to explore the mechanisms of GSP in alleviating RF. Finally, the mechanisms were comprehensively validated in vitro, and a rescue experiment was conducted by overexpressing HMGCR in HK-2 cells.
resultGSP inhibited TGF-β-induced HK-2 cell proliferation and migration and reduced Collagen I and α-SMA expression in vitro. Differential analysis of control vs. model groups revealed a total of 911 differentially expressed genes, including 374 downregulated and 537 upregulated genes. Of these, 225 genes were reversed after GSP treatment. PPI analysis indicated that HMGCR is the core target of GSP in alleviating RF, and molecular docking demonstrated a strong binding between GSP and HMGCR, which was further confirmed by CETSA. GO enrichment analysis revealed that the improvement of RF by GSP is closely related to biological processes such as cholesterol biosynthesis and metabolism. KEGG pathway enrichment analysis highlighted the significant roles of cholesterol metabolism and the NF-κB signaling pathway in GSP’s effect on RF. Western blot results confirmed that GSP significantly inhibited expression of HMGCR and activation of the NF-κB signaling pathway in TGF-β-induced HK-2 cells. This effect was significantly reversed upon overexpression of HMGCR, indicating that GSP exerts its anti-RF effects by downregulating HMGCR and inhibiting NF-κB pathway activation.
conclusionThis study confirms that GSP can inhibit the HMGCR/NF-κB pathway to protect against TGF-β-induced HK-2 cell injury, exhibiting favorable therapeutic potential for RF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.